Back to Journals » OncoTargets and Therapy » Volume 11

Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review

Authors Donato EM, Fernández-Zarzoso M, Hueso JA, de la Rubia J

Received 13 April 2018

Accepted for publication 31 May 2018

Published 6 August 2018 Volume 2018:11 Pages 4583—4590

DOI https://doi.org/10.2147/OTT.S141053

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Cristina Weinberg

Peer reviewer comments 2

Editor who approved publication: Dr Yao Dai


Eva M Donato,1 Miguel Fernández-Zarzoso,1 Jose Antonio Hueso,1 Javier de la Rubia1,2

1Hematology Service, University Hospital Doctor Peset, Valencia, Spain; 2Department of Internal Medicine, Universidad Católica de Valencia “San Vicente Mártir,” Valencia, Spain

Abstract: Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) account for ~10% and 2%–3% of all cases of lymphoid neoplasms, respectively. Up to 30% of patients with HL are refractory or relapse after first-line therapy, and elderly patients with HL represent a subgroup of patients with suboptimal responses to the currently available treatments. Five-year overall survival for ALCL patients is 50%–80% with conventional chemotherapy. Therefore, new therapeutic approaches are needed for these groups of patients. Brentuximab vedotin is a chimeric IgG1 anti-CD30 antibody–drug conjugate that has all the features that are necessary to make a substantive difference with the standard therapies in patients with HL and ALCL: a novel mechanism of action, single-agent activity, non-cross-resistance, and safety both in the relapsed-refractory and in the front-line setting. This review provides an update of the results of the most relevant clinical trials including brentuximab vedotin for patients with HL and ALCL conducted to date.

Keywords: anaplastic large-cell lymphoma, anti-CD30 antibody, brentuximab vedotin, Hodgkin lymphoma

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]